-
Posted by
Two Blokes Jul 29 -
Filed in
Stock
-
2 views
AstraZeneca PLC (LSE:AZN) has reiterated its full-year guidance for 2025, following a robust set of results for the second quarter and first half, and pointed to a series of significant late-stage trial successes across its research and development pipeline. The pharmaceutical group reported total revenue of $14.46 billion for the second quarter, up 12% compared with the same period last year at actual exchange rates, driven by double-digit growth in oncology and biopharmaceuticals.
